These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 32114747)

  • 1. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (
    Sly LM; Braun P; Woodcock BG
    Int J Clin Pharmacol Ther; 2020 Dec; 58(12):678-686. PubMed ID: 33141018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
    Wang J; Jiang M; Chen X; Montaner LJ
    J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
    Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
    J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
    Wang Q; Hu Z
    Int J Infect Dis; 2020 Jul; 96():618-620. PubMed ID: 32470601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
    Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Information on the COVID-19 Pandemic continued.
    Rock G
    Transfus Apher Sci; 2020 Aug; 59(4):102854. PubMed ID: 32660893
    [No Abstract]   [Full Text] [Related]  

  • 11. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
    Ye Q; Wang B; Mao J
    J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.
    Rodríguez Y; Novelli L; Rojas M; De Santis M; Acosta-Ampudia Y; Monsalve DM; Ramírez-Santana C; Costanzo A; Ridgway WM; Ansari AA; Gershwin ME; Selmi C; Anaya JM
    J Autoimmun; 2020 Nov; 114():102506. PubMed ID: 32563547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma in Covid-19: Possible mechanisms of action.
    Rojas M; Rodríguez Y; Monsalve DM; Acosta-Ampudia Y; Camacho B; Gallo JE; Rojas-Villarraga A; Ramírez-Santana C; Díaz-Coronado JC; Manrique R; Mantilla RD; Shoenfeld Y; Anaya JM
    Autoimmun Rev; 2020 Jul; 19(7):102554. PubMed ID: 32380316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Mansourabadi AH; Sadeghalvad M; Mohammadi-Motlagh HR; Rezaei N
    Life Sci; 2020 Oct; 258():118185. PubMed ID: 32750438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
    Garraud O
    Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19.
    Lin JH; Chen YC; Lu CL; Hsu YN; Wang WJ
    J Formos Med Assoc; 2020 Jun; 119(6):1116-1118. PubMed ID: 32359878
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 20. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".
    Meftahi GH; Jangravi Z; Sahraei H; Bahari Z
    Inflamm Res; 2020 Sep; 69(9):825-839. PubMed ID: 32529477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.